Device-related infections are among the most challenging complications in modern healthcare, affecting hundreds of thousands of people who rely on medical implants to treat life-threatening conditions. While these devices have transformed the lives of countless patients, they also create opportunities for bacteria to colonize and form protective communities that resist both the body’s immune system and standard treatments.

Understanding Treatment Goals and Challenges

When a medical device becomes infected, the primary goal of treatment is to completely eliminate the infection and restore the patient’s health and quality of life. This often requires a multidisciplinary approach involving infectious disease specialists, surgeons, and other healthcare providers working together to develop the best strategy for each individual patient. The treatment plan depends heavily on which device is infected, how severe the infection has become, and the patient’s overall health status.^[1][2]

Treatment approaches vary significantly based on the timing of infection. Early infections that occur within weeks of device implantation are typically caused by contamination during surgery, while late infections appearing months or years later often result from bacteria traveling through the bloodstream from other parts of the body. Understanding when and how the infection developed helps doctors choose the most effective treatment strategy.^[3]

Standard treatments approved by medical societies have been established for many types of device infections, but ongoing research continues to explore new therapies that may improve outcomes for patients. Clinical trials are testing innovative approaches that could offer better alternatives for people whose infections don’t respond well to current treatments. However, it’s important to understand that device infections remain difficult to treat, and prevention strategies are considered far more effective than attempting to cure established infections.^[1]

Standard Treatment Approaches for Device Infections

The cornerstone of treating most device-related infections involves two critical components: antimicrobial therapy using antibiotics and surgical removal of the infected device. This dual approach is necessary because bacteria that colonize medical devices form structures called biofilms, which are communities of microorganisms surrounded by a self-produced protective coating. This coating acts like a shield, making the bacteria inside much more resistant to both antibiotics and the body’s natural immune defenses.^[5]

Studies have demonstrated just how challenging biofilms are to treat. Research has shown that treating biofilm-protected bacteria with very high doses of the antibiotic tobramycin—far exceeding what would normally kill free-floating bacteria—only reduced the bacterial count by approximately 100-fold. In contrast, the same antibiotic dosage eliminated more than 99.999999% of freely suspended bacteria of the same species. This dramatic difference explains why antibiotics alone rarely cure device infections.^[5]

Antibiotic Therapy

When doctors suspect a device infection, they typically begin antibiotic treatment immediately, even before laboratory tests identify the specific bacteria involved. This initial treatment, called empirical therapy, usually targets staphylococcal bacteria, which are the most common causes of device infections. Staphylococcus aureus and coagulase-negative staphylococci like Staphylococcus epidermidis are responsible for the majority of these infections across all device types.^[3]

Once laboratory cultures identify the exact bacteria causing the infection, doctors adjust the antibiotic treatment to target that specific organism. This is called targeted therapy, and it typically produces better results with fewer side effects than broad-spectrum antibiotics. The specific antibiotics chosen depend on the bacteria identified and whether they show resistance to commonly used drugs. Many device infections are caused by bacteria that have developed resistance to multiple antibiotics, making treatment selection more complex.^[9]

The duration of antibiotic therapy varies considerably depending on the type of device infected and whether the device is removed. For cardiac implantable electronic devices like pacemakers and defibrillators, guidelines recommend continuing antibiotics for at least 14 days after device removal if only the pocket site is infected. However, if the infection has spread to the device leads or has caused inflammation of the heart’s inner lining (endocarditis), treatment typically continues for 4 to 6 weeks or longer.^[7]

For orthopedic device infections, such as infected joint replacements or fracture fixation devices, antibiotic therapy may continue for several weeks or even months. The exact duration depends on whether the infected device can be removed, whether new hardware needs to be implanted, and how well the patient responds to treatment.^[8]

Surgical Device Removal

Complete removal of the infected device is considered essential for curing most device-related infections. This is because biofilms are so resistant to antibiotics that they cannot be reliably eliminated while the device remains in the body. Studies have consistently shown that attempting to treat device infections with antibiotics alone, without removing the device, leads to high failure rates and increased risk of serious complications.^[7]

For cardiac devices, the surgical procedure involves removing not just the generator (the main device unit) but also all the leads that connect it to the heart. These leads can be challenging to remove because they may have become encased in scar tissue or adhered to blood vessel walls over time. Specialized extraction techniques have been developed to safely remove these leads, often using laser or mechanical sheaths that can break through the tissue holding the leads in place.^[19]

After removing an infected device, doctors must determine when and how to replace it if the patient still needs the device’s function. For cardiac devices, this typically involves a waiting period to ensure the infection has cleared before implanting a new device. The new device is usually placed on the opposite side of the chest to avoid the previously infected area. The timing of reimplantation is carefully balanced—waiting long enough to ensure infection clearance while not leaving the patient unprotected for too long.^[7]

For orthopedic device infections, treatment often involves a staged approach. In the first surgery, the infected implant is removed and the bone is thoroughly cleaned. The space may be filled with antibiotic-loaded cement or spacers that slowly release high concentrations of antibiotics locally. After several weeks or months of systemic antibiotic therapy, a second surgery is performed to implant a new device once the infection has been eradicated.^[8]

Side Effects and Complications

Antibiotic treatment for device infections can cause various side effects. Common problems include digestive upset such as nausea, vomiting, and diarrhea. Some antibiotics can affect kidney function, requiring regular blood tests to monitor kidney performance during treatment. Others may cause allergic reactions ranging from mild rashes to severe, life-threatening responses. Long-term antibiotic use can also disrupt the body’s normal bacterial communities, potentially leading to secondary infections such as Clostridioides difficile colitis.^[4]

Surgical removal of infected devices carries its own risks. These include bleeding, damage to surrounding tissues or blood vessels, and the possibility that pieces of the device may break off during removal. For cardiac device extractions, there is a risk of tearing the heart muscle or blood vessels, which could require emergency open-heart surgery to repair. Mortality rates for these procedures, while generally low at specialized centers, increase with the complexity of the case and the patient’s overall health status.^[7]

Patients who require temporary removal of a cardiac device face the risk of life-threatening heart rhythm problems during the period when they are without their device. Some may require temporary external pacing or defibrillation equipment until a new permanent device can be safely implanted.^[7]

Emerging Treatments Being Tested in Clinical Trials

Researchers around the world are actively investigating new approaches to prevent and treat device-related infections. These innovative strategies target different aspects of how bacteria colonize devices and form biofilms, offering hope for more effective treatments in the future. Clinical trials are evaluating these approaches in phases, starting with safety testing in small groups (Phase I), then examining effectiveness in larger groups (Phase II), and finally comparing new treatments to standard approaches in large-scale studies (Phase III).^[8]

Antibacterial Device Coatings and Materials

One of the most promising approaches involves coating medical devices with substances that prevent bacteria from attaching or kill them on contact. These coatings work by creating an environment on the device surface that is hostile to bacterial colonization, potentially stopping infections before they can establish themselves.^[8]

Antibiotic-eluting coatings represent one category of these preventive technologies. These coatings slowly release antibiotics from the device surface over time, creating high local concentrations that can kill bacteria trying to attach to the device. Different antibiotics have been incorporated into various coating materials, with some showing promising results in clinical studies. For cardiac devices, antibiotic-impregnated mesh envelopes that surround the device generator have been tested in clinical trials and shown to reduce infection rates compared to standard implantation techniques.^[12]

Silver-based coatings are another approach being investigated. Silver has natural antimicrobial properties that have been recognized for centuries. Modern technology has allowed researchers to incorporate silver nanoparticles or silver ions into device materials or coatings. These silver-containing surfaces can kill bacteria on contact without requiring antibiotics, potentially offering protection against antibiotic-resistant organisms. Clinical trials are evaluating whether silver-coated urinary catheters and vascular devices can reduce infection rates in real-world use.^[8]

Anti-Biofilm Agents

Since biofilms are such a critical factor in device infections, researchers are developing compounds specifically designed to disrupt or prevent biofilm formation. These anti-biofilm agents work through various mechanisms, such as preventing bacteria from attaching to surfaces, breaking down the protective coating around established biofilms, or making biofilm bacteria more susceptible to antibiotics and immune system attack.^[8]

Some experimental compounds target the signaling systems bacteria use to coordinate biofilm formation. Bacteria communicate with each other through chemical signals in a process called quorum sensing. By blocking these signals, researchers hope to prevent bacteria from organizing into biofilms in the first place. These quorum-sensing inhibitors are being tested in laboratory and animal studies, with some showing promise for preventing device infections.^[8]

Enzymes that break down the protective coating surrounding biofilms represent another experimental approach. These enzymes, called dispersin or DNase depending on their target, can digest the proteins or DNA that hold biofilm structures together. When used in combination with antibiotics, these enzymes may help treatments penetrate biofilms more effectively. Early-phase clinical trials are exploring whether adding these enzymes to standard antibiotic treatment can improve outcomes for patients with established device infections.^[8]

Immunotherapy Approaches

Researchers are investigating whether enhancing the immune system’s ability to fight device infections could improve treatment outcomes. One approach involves developing vaccines against the bacteria most commonly responsible for device infections, particularly Staphylococcus aureus. The idea is that vaccinated patients would have antibodies ready to attack these bacteria immediately if they encountered them during device implantation or afterward.^[8]

Clinical trials of anti-staphylococcal vaccines have been conducted with mixed results. While some vaccines successfully generated antibodies in study participants, they have not yet proven effective at preventing actual infections in large clinical trials. Researchers continue to refine these vaccines, testing different bacterial components and delivery methods to find an approach that provides reliable protection.^[8]

Another immunotherapy strategy involves using antibodies or immune-boosting substances to help patients clear existing infections. These treatments might be particularly valuable for patients whose own immune systems are weakened by underlying conditions or medications. Early research is exploring whether delivering concentrated antibodies against biofilm bacteria could help overcome the protective effects of the biofilm coating.^[8]

Novel Antimicrobial Substances

As antibiotic resistance becomes an increasingly serious problem, researchers are searching for entirely new types of antimicrobial substances. Some of these experimental treatments come from unexpected sources and work through mechanisms completely different from traditional antibiotics.^[8]

Antimicrobial peptides are short chains of amino acids (the building blocks of proteins) that can kill bacteria by disrupting their outer membranes. These peptides are part of the body’s natural defense system, and synthetic versions are being developed as potential treatments. Because they work differently from antibiotics, they may be effective against antibiotic-resistant bacteria. Some antimicrobial peptides are being incorporated into device coatings, while others are being tested as injectable treatments.^[8]

Bacteriophages, or phages, are viruses that specifically infect and kill bacteria. Each type of phage typically targets only one or a few species of bacteria, making them highly specific weapons against particular infections. Phage therapy was used to treat bacterial infections before antibiotics were discovered but fell out of favor when antibiotics proved more convenient. Now, with antibiotic resistance rising, researchers are taking a fresh look at phages. Early-phase clinical trials are testing whether phages can be used to treat device infections, particularly those caused by antibiotic-resistant bacteria.^[8]

Location-Specific Antimicrobial Delivery

Rather than giving antibiotics throughout the entire body (systemic therapy), researchers are developing methods to deliver high concentrations of antimicrobials directly to infected devices. This approach could potentially overcome biofilm resistance while minimizing side effects from systemic antibiotic exposure.^[8]

For bone infections associated with orthopedic devices, antibiotic-loaded bone cement and other local delivery systems are already in clinical use and continue to be refined. These materials can release antibiotics at the infection site for weeks or months, achieving local concentrations far higher than could be safely achieved throughout the body. Clinical studies are evaluating which antibiotics work best in these delivery systems and how long they should remain in place.^[8]

For vascular and cardiac device infections, researchers are investigating whether catheters could be used to deliver antimicrobials directly to infection sites. Some studies are testing whether antimicrobial-containing gels or solutions instilled into device pockets or along catheter paths could help clear localized infections without requiring complete device removal.^[8]

Prevention Strategies: The Best Approach

Medical guidelines consistently emphasize that preventing device infections in the first place is far more effective and safer than treating established infections. Multiple prevention strategies have been developed based on research identifying risk factors and infection pathways. These preventive measures are applied before, during, and after device implantation.^[12]

Pre-Procedure Preparation

Before device implantation, several steps can reduce infection risk. Screening for and treating active infections elsewhere in the body is important because bacteria from these sites can travel through the bloodstream and colonize newly implanted devices. Patients with skin infections, urinary tract infections, or dental infections should have these treated before elective device implantation when possible.^[12]

Certain patients carry staphylococcal bacteria on their skin or in their nose without having any symptoms of infection. This is called colonization. Studies have shown that patients colonized with Staphylococcus aureus face higher risks of device infection. Some medical centers screen patients for nasal carriage before device implantation and treat carriers with topical antibacterial ointments to eliminate the bacteria. This decolonization strategy has been shown in some studies to reduce infection rates.^[12]

Optimizing patients’ overall health before surgery can also help. Controlling blood sugar levels in diabetic patients, improving nutritional status in malnourished individuals, and reviewing medications that might increase infection risk are all important preparatory steps. Patients are typically advised to wash with antibacterial soap before surgery to reduce the bacterial load on their skin.^[12]

Procedural Techniques

During device implantation, strict sterile technique is essential. This includes thorough skin preparation with antiseptic solutions, use of sterile drapes and equipment, and careful handling of the device to minimize contamination. Studies have shown that even brief lapses in sterile technique can significantly increase infection rates.^[12]

Prophylactic antibiotics given just before the procedure are standard practice for nearly all device implantations. These antibiotics, typically directed against staphylococcal bacteria, should be administered within one hour before the skin incision to ensure adequate tissue concentrations during the procedure. The specific antibiotic chosen depends on local bacterial resistance patterns and patient allergies. Guidelines recommend a single dose for most procedures, though some complex cases may warrant longer courses.^[12]

Minimizing procedure duration and tissue trauma can also reduce infection risk. Prolonged surgeries and extensive tissue manipulation create more opportunities for bacterial contamination and reduce the tissues’ ability to resist infection. Experienced operators performing procedures efficiently with minimal tissue damage achieve lower infection rates than those still developing their skills.^[12]

Post-Procedure Care

After device implantation, careful wound care and monitoring for signs of infection are critical. Dressings should be kept clean and dry, and patients should be educated about signs of infection that warrant immediate medical attention. These include increasing redness, warmth, swelling, or drainage from the wound site, as well as fever or other systemic symptoms.^[12]

The timing of first dressing change and wound inspection varies by procedure type, but early identification of problems allows for prompt intervention. Patients should be instructed to avoid activities that might stress the wound or introduce contamination during the healing period.^[12]

For patients with implanted devices, maintaining good hygiene and promptly treating infections at other body sites throughout the device’s lifetime remains important. Since bacteria from distant infections can seed devices through the bloodstream, managing other health problems conscientiously can reduce late infection risk.^[12]

Most Common Treatment Methods

• Antibiotic Therapy
  • Empirical treatment targeting staphylococcal bacteria started immediately when infection is suspected
  • Targeted therapy adjusted based on laboratory culture results identifying specific bacteria
  • Treatment duration typically ranges from 14 days to several months depending on device type and infection severity
  • Combination therapy using multiple antibiotics may be used for resistant organisms or severe infections
• Surgical Device Removal
  • Complete extraction of infected device and all associated components (leads, cement, hardware)
  • Specialized extraction techniques for cardiac devices using laser or mechanical sheaths
  • Staged procedures for orthopedic infections with temporary antibiotic spacers before reimplantation
  • Thorough debridement of infected tissues surrounding the device
• Local Antimicrobial Delivery
  • Antibiotic-loaded bone cement for orthopedic device infections
  • Antibiotic spacers placed temporarily in infected sites
  • Antibiotic-impregnated beads providing sustained local drug release
• Preventive Interventions
  • Prophylactic antibiotics administered before device implantation procedures
  • Antibacterial envelope pouches surrounding cardiac devices during implantation
  • Preoperative nasal decolonization to eliminate Staphylococcus aureus carriers
  • Strict sterile technique during all device implantation and revision procedures
• Device Replacement Strategies
  • Delayed reimplantation after infection clearance documented by clinical and laboratory criteria
  • Alternative site selection for new device placement when possible
  • Temporary external devices bridging the gap between removal and reimplantation